top of page

Servier's U.S. CEO discusses FDA approval of Voranigo, a targeted therapy for a common type of brain cancer

  • blonca9
  • Aug 7, 2024
  • 1 min read

David Lee describes the glioma brain cancer population this IHD1/2 targeting therapy is for, Servier's experience commercializing cancer medicines, and how he thinks about deals going forward.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page